Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05459402 · ClinicalTrials.gov registry record · Phase 2
Divided or Single Exposure (DOSE) Study
A Phase 2 study of Chronic Pain and Opioid Use Disorder, sponsored by University of Maryland, Baltimore.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 1
- Study location
NCT05459402: Recruiting Phase 2 study of Chronic Pain and Opioid Use Disorder, sponsored by University of Maryland, Baltimore.
NCT05459402 is a Phase 2 study of Chronic Pain and Opioid Use Disorder that is actively recruiting participants, run by University of Maryland, Baltimore. The registered enrollment target is 150 participants, below the 772-participant average among 301 other Chronic Pain trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05459402, a Phase 2 study of Chronic Pain and Opioid Use Disorder, is actively recruiting participants, sponsored by University of Maryland, Baltimore.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate whether once versus twice daily dosing of methadone will be an effective method for managing comorbid pain and opioid use disorder.
Primary Outcome
Using the Brief Pain Inventory rating of "Worst Pain" in the past 24 hours, rated on a scale of 1-10, collected once weekly during weeks 1 through 12 of the intervention.
Conditions Studied
Interventions
- DRUG Methadone (100% dose)
- DRUG Methadone (50% dose)
Study Locations (1)
Maryland
- Addiction Treatment Services (ATS) - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2023-02-21 |
| Est. Completion | 2028-06-01 |
| Phase | Phase 2 |
What NCT05459402 shows while recruiting
NCT05459402 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 301 other Chronic Pain trials with a reported enrollment target (81% lower).
The record links to 3 conditions, with Chronic Pain appearing as the primary indexed condition, and to 2 interventions - of which Methadone (100% dose) is the first listed.
NCT05459402 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT05459402 about?
NCT05459402 is a clinical study titled "Divided or Single Exposure (DOSE) Study". This study will evaluate whether once versus twice daily dosing of methadone will be an effective method for managing comorbid pain and opioid use disorder.
What is the current status of trial NCT05459402?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2023-02-21. Estimated completion is 2028-06-01.
What conditions does trial NCT05459402 study?
This clinical trial studies the following conditions: Chronic Pain, Opioid Use Disorder, Methadone.
What interventions are being tested in trial NCT05459402?
The interventions under investigation include: Methadone (100% dose) (DRUG), Methadone (50% dose) (DRUG).
Who is sponsoring clinical trial NCT05459402?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05459402 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05459402's enrollment target sits among peer trials
150 103rd of 301 higher than 196 of 301 other Chronic Pain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PAIN: a Project Assessing the Impact of a Novel Cannabinoid Product
RECRUITING · Phase 2
-
The Role of Brain Dopamine in Chronic Pain
RECRUITING · Phase 2
-
Generate and Test the Reliability of a PD Model of OXT on Pupillary Hippus as a Measure of CNS Activity
RECRUITING · Phase 2
-
A Mobile Intervention to Reduce Pain and Improve Health-III
RECRUITING · Phase 2
-
Dronabinol as an Adjunct for Reducing Pain
RECRUITING · Phase 2
-
Pilot Study: Impact of Biomarker-Guided Dietary Supplementation on Quality-of-Life Measures in Subjects With Chronic Pain
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI